time for a reasonable discussion, page-2

  1. 506 Posts.
    Nice Sum Zaskar

    just to add to your discussion...

    Daratumumab, a "non orphan-drug", received "Breakthrough therapy destination" by the USFDA while in phase 1/2 (May 2013).

    Janssen (Sub of J&J) made a potential billion $ deal with Genmab during 2012 while Daratumumab was still in phase 1/2.


    http://www.firstwordpharma.com/node/1013741#axzz2l5ccGSt8

    http://www.onclive.com/web-exclusives/Breakthrough-Designation-Granted-to-Daratumumab-for-Double-Refractory-Multiple-Myeloma
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.2¢
Change
0.000(0.00%)
Mkt cap ! $4.731M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
37 93363115 0.1¢
 

Sellers (Offers)

Price($) Vol. No.
0.2¢ 55215191 23
View Market Depth
Last trade - 16.21pm 17/07/2025 (20 minute delay) ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.